Hello, I am Dr. Hidenori Shimada of Grand Green Osaka Umekita Clinic in Osaka, Japan.
When people first hear about cancer immune cell therapy, one of their earliest practical questions is simple: will I have to stay in the hospital? For patients who are already managing standard cancer care, work, family, or travel from abroad, the answer matters a great deal. This article explains how NK cell therapy is organized as an outpatient treatment at Grand Green Osaka Umekita Clinic in Osaka, what a typical visit may involve, and which questions are worth raising with a doctor before you decide.
This article is general information, not medical advice. Whether this therapy is suitable for you can only be judged by a physician after a consultation.
The short answer: it is designed as an outpatient therapy
NK cell therapy, as described on the clinic’s treatment page, involves a standard blood draw and, later, an intravenous infusion. It does not involve hospitalization. That is because the most complex part of the process happens outside your body, at a specialized cell processing facility, rather than at your bedside.
NK (natural killer) cells are innate immune cells that patrol the body and respond to cancer cells and virus-infected cells. Their activity is known to decline with age, stress, and the effects of cancer itself. In this therapy, NK cells obtained from your own blood are activated and expanded, and then returned to you by infusion. Because the cells come from you, the approach is called autologous cell therapy.
An outpatient format does not mean the therapy is simple or free of questions. It simply means that, in general, you arrive at the clinic, receive the procedure for that day, and then return to your own accommodation or home. Your doctor will explain what applies to your situation.
What each step may look like for you
Although the exact schedule is set by the doctor, the overall flow can be understood in three stages.
- Consultation and blood draw. You meet a physician, discuss your medical history and current treatment, and, if you proceed, have blood collected in a way similar to a routine blood test.
- Activation and expansion outside the body. The collected NK cells are processed at a licensed facility. You do not need to be present during this period.
- Infusion. The prepared cells are returned through an IV drip at the clinic, and you are observed by the medical team.
The waiting period between the blood draw and the infusion is an important planning point, especially for international patients. Ask the clinic how long each stage typically takes, how many visits are expected, and whether any steps can be coordinated around your travel plans. Do not assume a timetable from general descriptions; your doctor should confirm it for you.
Daily life during treatment: what is reasonable to expect
Because treatment consists of a blood draw and an infusion without a hospital stay, many people are able to continue much of their normal routine around clinic visits. The clinic describes this as an approach that is gentle on the body in the sense that it avoids hospitalization. However, how you feel will differ from person to person, and it also depends on any other cancer treatment you are receiving.
Some people may experience temporary fever or fatigue after an infusion. Because everyone responds differently, it is sensible to plan a lighter schedule on infusion days and to ask your doctor in advance what symptoms are expected, what symptoms need a call to the clinic, and who to contact if something worries you after you leave. If you are traveling, find out how you could reach a doctor if you feel unwell once you are back in your hotel or after you fly home.
If you work, it can help to discuss with your employer in advance whether you need flexible hours on treatment days. If you are a caregiver or a parent, consider who can help on those days. These are practical questions, but they are part of preparing well.
Outpatient care and standard cancer treatment
NK cell therapy is not presented as a replacement for standard cancer treatment. According to the clinic’s information, it can be considered alongside surgery, chemotherapy, or radiation therapy, and the clinic can coordinate with the medical institution that provides your standard care. Whether and when it can be combined is a decision for your physicians, not something to decide on your own.
If your oncologist is in another city or another country, bring your latest medical records and ask your oncologist whether they are comfortable with the plan. Good coordination between the two teams is one of the most useful things you can arrange before any infusion takes place. It is also worth asking how the schedule of your standard treatment, for example chemotherapy cycles, might affect the timing of the blood draw.
The therapy may also be considered by people who wish to maintain immune function or who have finished cancer treatment and are thinking about recurrence prevention. Even then, the goal should be discussed realistically: researchers continue to study cell-based immunotherapies, and no one can promise a particular outcome for an individual patient.
Cost, regulation, and what a doctor needs to confirm
NK cell therapy is a self-pay (non-insured) treatment in Japan, so it is not covered by national health insurance. Fees, the number of treatments, the expected duration, risks, and possible side effects should all be explained to you in writing and in a language you understand before you agree to anything. Ask what is included in the fee and whether additional visits or tests could add to the total.
In Japan, cell therapies of this kind are provided under the Act on the Safety of Regenerative Medicine, which requires a treatment plan to be submitted to and accepted by the government. This framework is meant to support safety management, but it does not mean that outcomes are assured. You are entitled to ask the clinic about its plan, its processing facility, and how adverse events are handled.
Suitability, risks, and expected benefits differ with your cancer type, stage, medications, and overall health. Only a doctor who has examined you and reviewed your records can discuss these points properly.
Questions to bring to your consultation in Osaka
Preparing a short list can make a first consultation more productive. You may wish to ask the following.
- How many clinic visits are expected, and how long is each visit?
- How much time passes between the blood draw and the infusion?
- What temporary symptoms can occur, and when should I contact the clinic?
- How will you coordinate with my current oncologist or hospital?
- What is the total self-pay cost, and what is not included?
- What language support is available, including interpretation and written consent materials?
- What should I do if I feel unwell after returning home or abroad?
Grand Green Osaka Umekita Clinic is located in Umeda, Osaka, and offers information pages in several languages for international patients, including a page for foreign visitors. If you are traveling for medical care, reading these pages before your consultation can help you prepare your questions and your records.
Summary
NK cell therapy is organized around a blood draw and an IV infusion without hospitalization, which can make it easier to fit around work, family life, and standard cancer treatment. Still, an outpatient format is not a guarantee of comfort or benefit. Plan for possible temporary fever or fatigue, confirm the schedule and total cost in advance, and make sure your own oncologist is informed.
Because this is a self-pay treatment provided under Japan’s regenerative medicine framework, the most important step is a consultation in which a doctor reviews your situation and explains the possible benefits, limits, and risks in a language you understand. Please use this article only as a starting point for that conversation.
- 1ConsultationDoctor reviews your case
- 2Blood drawSimilar to a routine test
- 3Cell processingDone at a licensed facility
- 4IV infusionOutpatient, no hospital stay
This diagram is a conceptual summary of the article content
References
- PubMed: The use of BRM-activated killer cells in adoptive immunotherapy: a pilot study with nine advanced cancer patients. (1998)
- PubMed: Life-prolonging effect of immunocell BAK (BRM-activated killer) therapy for advanced solid cancer patients: prognostic significance of serum immunosuppressive acidic protein levels. (2003)
- PubMed: Effector mechanism and clinical response of BAK (BRM-activated killer) immuno-cell therapy for maintaining satisfactory QOL of advanced cancer patients utilizing CD56-positive NIE (neuro-immune-endocrine) cells. (2001)
- MHLW (Japan): Regenerative Medicine — Ministry of Health, Labour and Welfare, Japan
Supervising Physician
Director, Medical Corporation Shimada Clinic
Head of Clinical Practice, Grand Green Osaka Umekita Clinic
Hidenori Shimada
Graduated from the University of Tokushima Faculty of Medicine in 2005. After his initial residency, he obtained U.S. medical certification (ECFMG) and trained as a sub-intern in general surgery at the University of Washington. After completing the doctoral program at Kyoto University Graduate School of Medicine and working as a researcher at the Center for iPS Cell Research and Application (CiRA), Kyoto University, he founded Shimada Clinic in 2013. At Grand Green Osaka Umekita Clinic (https://umekitaclinic.org), he is engaged in a wide range of care, from internal medicine and pediatrics to cell therapy and aesthetic medicine.
* The physician supervision of this article covers its academic content only and does not constitute a recommendation of any specific treatment or product.